Efficacy and safety of pimecrolimus-eluting stents in porcine coronary arteries

Cardiovascular Revascularization Medicine

Volumn 8, Issue 4, 2007, Pages 259-274

  Waksman, Ron ^a   Pakala, Rajbabu ^a   Baffour, Richard ^a   Hellinga, David ^a   Seabron, Rufus ^a   Tio, Fermin O ^b   Wittchow, Eric ^c   Tittelbach, Michael ^c   Diener, Tobias ^c   Harder, Claus ^c   Virmani, Renu ^d   Jones, Russel ^d  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^c Biotronik GmbH and Co KG   (Germany)

^d CVPATH INSTITUTE   (United States)

Author keywords

In stent restenosis; Pimecrolimus eluting stent; Porcine

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CLOPIDOGREL; PIMECROLIMUS; POLYLACTIC ACID;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL OCCLUSION; CONTROLLED STUDY; CORONARY ARTERY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG SAFETY; FEMALE; IN-STENT RESTENOSIS; INFLAMMATION; LOW DRUG DOSE; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; STENT; SWINE; TREATMENT DURATION; VASCULAR PATENCY;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DRUG-ELUTING STENTS; RANDOM ALLOCATION; STATISTICS, NONPARAMETRIC; SWINE; TACROLIMUS; TIME FACTORS; TUNICA INTIMA; ULTRASONOGRAPHY, INTERVENTIONAL; VASCULAR PATENCY; WOUND HEALING;

EID: 36348986263     PISSN: 15538389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carrev.2007.09.003     Document Type: Article

References (68)

1. Kornowski R., Hong M., Tio F., Bramwell O., Wu H., and Leon M. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 31 (1998) 224-230
2. Hayashi S., Watanabe N., Nakazawa K., Suzuki J., Tsushima K., Tamatani T., Sakamoto S., and Isobe M. Roles of P-selectin in inflammation, neointimal formation, and vascular remodeling in balloon-injured rat carotid arteries. Circulation 102 (2000) 1710-1717
3. Okamoto E., Couse T., De Leon H., Suzuki J., Tsushima K., Tamatani T., Sakamoto S., and Isobe M. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation 104 (2001) 2228-2235
4. Breuss J., Cejna M., Bergmeister H., Kadl A., Baumgartl G., Steurer S., Xu Z., Koshelnick Y., Lipp J., De Martin R., Losert U., Lammer J., and Binder B. Activation of nuclear factor-kappa B significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model. Circulation 105 (2002) 633-638
5. Zhou Z., Lauer M., Wang K., Forudi F., Zhou X., Song X., Solowski N., Kapadia S., Nakada M., Topol E., and Lincoff A. Effect of anti-tumor necrosis factor-alpha polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model. Atherosclerosis 161 (2002) 153-159
6. Farb A., Weber D., Kolodgie F., Burke A., and Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation 105 (2002) 2974-2980
7. Mickelson J., Lakkis N., Villarreal-Levy G., Hughes B., and Smith C. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease?. J Am Coll Cardiol 28 (1996) 345-353
8. Serrano Jr. C., Ramires J., Venturinelli M., Arie S., D'Amico E., Zweier J., Pileggi F., and da Luz P. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol 29 (1997) 1276-1283
9. Cipollone F., Marini M., Fazia M., Pini B., Iezzi A., Reale M., Paloscia L., Materazzo G., D'Annunzio E., Conti P., Chiarelli F., Cuccurullo F., and Mezzetti A. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 21 (2001) 327-334
10. Schillinger M., Exner M., Mlekusch W., Haumer M., Ahmadi R., Rumpold H., Wagner O., and Minar E. Balloon angioplasty and stent implantation induce a vascular inflammatory reaction. J Endovasc Ther 9 (2002) 59-66
11. Bhatia V., Bhatia R., and Dhindsa M. Drug-eluting stents: new era and new concerns. Postgrad Med J 80 (2004) 13-18
12. Marx S., and Marks A. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 104 (2001) 852-855
13. Grassberger M., Baumruker T., Enz A., Hiestand P., Hultsch T., Kalthoff F., Schuler W., Schulz M., Werner F., Winiski A., Wolff B., and Zenke G. Novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 141 (1999) 264-273
14. Gupta A., and Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol 17 (2003) 493-503
15. Hultsch T., Muller K., Meingassner J., Grassberger M., Schopf R., and Knop J. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res 290 (1998) 501-507
16. Schwartz R., Huber K., Murphy J., Edwards W., Camrud A., Vlietstra R., and Holmes D. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 19 (1992) 267-274
17. Carter A., Aggarwal M., Kopia G., Tio F., Tsao P., Kolata R., Yeung A., Llanos G., Dooley J., and Falotico R. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 63 (2004) 617-624
18. Farb A., Heller P., Shroff S., Cheng L., Kolodgie F., Carter A., Scott D., Froehlich J., and Virmani R. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104 (2001) 473-479
19. Schwartz R., Chronos N., and Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol 44 (2004) 1373-1385
20. Schwartz R., Edelman E., Carter A., Chronos N., Rogers C., Robinson K., Waksman R., Weinberger J., Wilensky R., Jensen D., Zuckerman B., and Virmani R. Consensus Committee. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation 106 (2002) 1867-1873
21. Taylor A. Metals. In: Sigwart U. (Ed). Endoluminal stenting (1996), W.B. Saunders Company, Ltd, London 28-33
22. Haudrechy P. Nickel release from 304 and 316 stainless steels in synthetic sweat. Comparison with nickel and nickel-plated metals. Consequences on allergic contact dermatitis. Corros Sci 35 (1993) 329-336
23. Park J., and Kim Y. Metallic biomaterials. In: Park J., and Bronzino J. (Eds). Biomaterials principles and applications (2003), CRC Press, Boca Raton 1-20
24. Kereiakes D., Cox D., Hermiller J., Midei M., Bachinsky W., Nukta E., Leon M., Fink S., Marin L., and Lansky A. Guidant Multi-Link Vision Stent Registry Investigators. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol 92 (2003) 463-466
25. Gotman I. Characteristics of metals used in implants. J Endourol 11 (1997) 383-389
26. Granchi D., Ciapetti G., Savarino L., Cavedagna D., Donati M., and Pizzoferrato A. Assessment of metal extract toxicity on human lymphocytes cultured in vitro. J Biomed Mater Res 31 (1996) 183-191
27. Ermolli M., Menné C., Pozzi G., Serra M., and Clerici L. Nickel, cobalt and chromium-induced cytotoxicity and intracellular accumulation in human hacat keratinocytes. Toxicology 159 (2001) 23-31
28. Bolz A., and Schaldach M. Artificial heart valves: improved blood compatibility by PECVD a-SiC:H coating. Artif Organs 14 (1990) 260-269
29. Monnink S., van Boven A., Peels H., Tigchelaar I., de Kam P., Crijns H., and van Oeveren W. Silicon-carbide coated coronary stents have low platelet and leukocyte adhesion during platelet activation. J Investig Med 47 (1999) 304-310
30. Kalnins U., Erglis A., Dinne I., Kumsars I., and Jegere S. Clinical outcomes of silicon carbide coated stents in patients with coronary artery disease. Med Sci Monit 8 (2002) PI16-PI20
31. Köster R., Vieluf D., Kiehn M., Sommerauer M., Kähler J., Baldus S., Meinertz T., and Hamm C. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet 356 (2000) 1895-1897
32. Virmani R., Guagliumi G., Farb A., Musumeci G., Grieco N., Motta T., Mihalcsik L., Tespili M., Valsecchi O., and Kolodgie F. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 (2004) 701-705
33. Revell P., Braden M., and Freeman M. Review of the biological response to a novel bone cement containing poly (ethyl methacrylate) and n-butyl methacrylate. Biomaterials 19 (1998) 1579-1586
34. Niemi S., Fox J., Brown L., and Langer R. Evaluation of ethylene-vinyl acetate copolymer as a non-inflammatory alternative to Freund's complete adjuvant in rabbits. Lab Anim Sci 35 (1985) 609-612
35. Peltonen L., Jero J., Sukura A., Pietola L., Konttinen Y., and Aarnisalo A. Biocompatibility of polylactides in the middle ear: an experimental animal study. Otol Neurotol 28 (2007) 850-853
36. Schmidmaier G., Baehr K., Mohr S., Kretschmar M., Beck S., and Wildemann B. Biodegradable polylactide membranes for bone defect coverage: biocompatibility testing, radiological and histological evaluation in a sheep model. Clin Oral Implants Res 17 (2006) 439-444
37. Agrawal C., Haas K., Leopold D., and Clark H. Evaluation of poly (l-lactic acid) as a material for intravascular polymeric stents. Biomaterials 13 (1992) 176-182
38. Tamai H., Igaki K., Kyo E., Kosuga K., Kawashima A., Matsui S., Komori H., Tsuji T., Motohara S., and Uehata H. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102 (2000) 399-404
39. Welt F., and Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 22 (2002) 1769-1776
40. Colombo A., and Sangiorgi G. The monocyte: the key in the lock to reduce stent hyperplasia?. J Am Coll Cardiol 43 (2004) 24-26
41. Komatsu R., Ueda M., Naruko T., Kojima A., and Becker A. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation 98 (1998) 224-233
42. Farb A., Sangiorgi G., Carter A., Walley V., Edwards W., Schwartz R., and Virmani R. Pathology of acute and chronic coronary stenting in humans. Circulation 99 (1999) 44-52
43. Welt F., Edelman E., Simon D., and Rogers C. Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries. Arterioscler Thromb Vasc Biol 20 (2000) 2553-2558
44. Rogers C., Welt F., Karnovsky M., and Edelman E. Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol 16 (1996) 1312-1318
45. Rogers C., Edelman E., and Simon D. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci U S A 95 (1998) 10134-10139
46. Mori E., Komori K., Yamaoka T., Tanii M., Kataoka C., Takeshita A., Usui M., Egashira K., and Sugimachi K. Essential role of monocyte chemoattractant protein-1 in development of restenotic changes (neointimal hyperplasia and constrictive remodeling) after balloon angioplasty in hypercholesterolemic rabbits. Circulation 105 (2002) 2905-2910
47. Meingassner J., Aschauer H., Stuetz A., and Billich A. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin. Exp Dermatol 14 (2005) 752-757
48. Nghiem P., Pearson G., and Langley R. Tacrolimus and pimecrolimus: From clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 46 (2002) 228-241
49. Aramburu J., Rao A., and Klee C. Calcineurin: from structure to function. Curr Top Cell Regul 36 (2000) 237-295
50. Shibasaki F., Hallin U., and Uchino H. Calcineurin as a multifunctional regulator. J Biochem (Tokyo) 131 (2002) 1-15
51. Rao A., Luo C., and Hogan P. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 15 (1997) 707-747
52. Liu Z., Dronadula N., and Rao G. A novel role for nuclear factor of activated T cells in receptor tyrosine kinase and G-protein-coupled receptor agonist-induced vascular smooth muscle cell motility. J Biol Chem 279 (2004) 41218-41226
53. Yellaturu C., Ghosh S., Rao R., Jennings L., Hassid A., and Rao G. A potential role for nuclear factor of activated T-cells in receptor tyrosine kinase and G-protein-coupled receptor agonist-induced cell proliferation. Biochem J 368 (2002) 183-190
54. Yu H., Sliedregt-Bol K., Overkleeft H., van der Marel G., van Berkel T., and Biessen E. Therapeutic potential of a synthetic peptide inhibitor of nuclear factor of activated T cells as Antirestenotic Agent. Arterioscler Thromb Vasc Biol 26 (2006) 1531-1537
55. Salu K., Liu X., Li S., Wang L., Verbeken E., Bosmans J., and De Scheerder I. Methotrexate loaded SAE coated coronary stents reduce neointimal hyperplasia in a porcine coronary model. Heart 90 (2004) 195-199
56. Wang L., Salu K., Verbeken E., Bosmans J., Van de Werf F., De Scheerder I., and Huang Y. Stent mediated methylprednisolone delivery reduces macrophage contents and in-stent neointimal formation. Coron Artery Dis 16 (2005) 237-243
57. Salu K., Bosmans J., Huang Y., Hendriks M., Verhoeven M., Levels A., Cooper S., De Scheerder I., Vrints C., and Bult H. Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine coronary artery model. Cardiovasc Res 69 (2006) 536-544
58. Suzuki T., Kopia G., Hayashi S., Bailey L., Llanos G., Wilensky R., Klugherz B., Papandreou G., Narayan P., Leon M., Yeung A., Tio F., Tsao P., Falotico R., and Carter A. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104 (2001) 1188-1193
59. Carter A., Brodeur A., Collingwood R., Ross S., Gibson L., Wang C., Haller S., Coleman L., and Virmani R. Experimental efficacy of an everolimus eluting cobalt chromium stent. Catheter Cardiovasc Interv 68 (2006) 97-103
60. Hong M., Kornowski R., Bramwell O., Ragheb A., and Leon M. Paclitaxel-coated Gianturco-Roubin II (GR II) stents reduce neointimal hyperplasia in a porcine coronary in-stent restenosis model. Coron Artery Dis 12 (2001) 513-515
61. Jabara R., Chronos N., Tondato F., Conway D., Molema W., Park K., Mabin T., King S., and Robinson K. Toxic vessel reaction to an absorbable polymer-based paclitaxel-eluting stent in pig coronary arteries. J Invasive Cardiol 18 (2006) 383-390
62. Grube E., Sonoda S., Ikeno F., Honda Y., Kar S., Chan C., Gerckens U., Lansky A., and Fitzgerald P. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 109 (2004) 2168-2171
63. Burke A., Kolodgie F., Zieske A., Fowler D., Weber D., Varghese P., Farb A., and Virmani R. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 24 (2004) 1266-1271
64. Jander S., Sitzer M., Schumann R., Schroeter M., Siebler M., Steinmetz H., and Stoll G. Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization. Stroke 29 (1998) 1625-1630
65. De Palma R., Del Galdo F., Abbate G., Chiariello M., Calabró R., Forte L., Cimmino G., Papa M., Russo M., Ambrosio G., Giombolini C., Tritto I., Notaristefano S., Berrino L., Rossi F., and Golino P. Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque: evidence for a local, intracoronary immunologic mechanism. Circulation 113 (2006) 640-646
66. Clausell N., de Lima V., Molossi S., Liu P., Turley E., Gotlieb A., Adelman A., and Rabinovitch M. Expression of tumour necrosis factor alpha and accumulation of fibronectin in coronary artery restenotic lesions retrieved by atherectomy. Br Heart J 73 (1995) 534-539
67. Osada M., Takeda S., Ogawa R., Komori S., and Tamura K. T lymphocyte activation and restenosis after percutaneous transluminal coronary angioplasty. J Interferon Cytokine Res 21 (2001) 219-221
68. Andersen H., Hansen B., Holm P., Stender S., and Nordestgaard B. Effect of cyclosporine on arterial balloon injury lesions in cholesterol-clamped rabbits: T lymphocyte-mediated immune responses not involved in balloon injury-induced neointimal proliferation. Arterioscler Thromb Vasc Biol 19 (1999) 1687-1694